A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending and Multiple Ascending Doses of Prosetin in Healthy Volunteers and Participants with Amyotrophic Lateral Sclerosis (ALS) with an Optional Open-Label Extended Treatment Period for ALS Participants who Complete 14 Days of Blinded Treatment

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2023
This article has no abstract
Epistemonikos ID: 42f0b3a9da1de60c0f0779c099ef65ab89c356f0
First added on: Mar 21, 2025